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Abstract: Respiratory syncytial virus (RSV) is a leading cause of hospitalization in children 
less than 1 year of age and causes substantial morbidity. Although there is not currently a vac-
cine available to prevent RSV infection, prophylaxis with the humanized monoclonal antibody 
palivizumab has been shown to reduce the rate of RSV hospitalization in premature infants 
and those infants with chronic lung disease or congenital heart disease. Because palivizumab 
has not been shown to have a beneﬁ  cial clinical effect on established RSV disease such as 
reducing the rate of mechanical ventilation and mortality in children afﬂ  icted with RSV, there 
has been considerable debate as to the cost-beneﬁ  t ratio of administering palivizumab accord-
ing to international guidelines. Palivizumab has demonstrated a favorable side-effect proﬁ  le 
in clinical trials without the development of anti-palivizumab antibodies. Future studies are 
needed to determine whether palivizumab, or other more potent monoclonal antibodies which 
are currently undergoing clinical trials, will reduce the long-term sequelae of RSV infection 
such as the development of wheezing and asthma.
Keywords: monoclonal antibodies, palivizumab, respiratory syncytial virus, immunoprophy-
laxis, pediatrics
Introduction
Despite recent recognition that rhinoviruses (Kusel et al 2006) and human metapneu-
movirus (Wolf et al 2006) are important lower respiratory pathogens in children, 
respiratory syncytial virus (RSV) remains the leading cause of hospitalization for 
respiratory tract illness in infants <1 year of age with 2%–3% of affected infants requir-
ing hospitalization (Hall 2001; Leader and Kohlhase 2003; Holman et al 2004). In the 
United States, RSV is the most common viral cause of death in children younger than 5 
years of age, particularly in children younger than 1 year of age (Thompson et al 2003). 
Children with a history of premature birth, congenital heart disease (CHD), neurological 
disorders (Purcell and Fergie 2004), bronchopumonary dysplasia (BPD) (Boyce et al 
2000), other pre-existing lung disorders (Arnold et al 1999), immunosuppression (Hall 
et al 1986), and genetic syndromes (Fjaerli et al 2004) are at increased risk of developing 
severe RSV infection. While hospitalized with RSV, children are at risk for experienc-
ing complications and injuries resulting from an error in medical management which 
can lead to a prolonged length of stay and higher costs (Willson et al 2003; McBride 
et al 2005). In addition, the effects of RSV may not end after hospitalization since 
there is considerable debate as to whether RSV bronchiolitis in infancy contributes 
to the development of asthma later in childhood. Some investigators have noted an 
increased prevalence of asthma later in life in children who acquired RSV at an early 
age (Sigurs et al 2000, 2005; Henderson et al 2005) while others have not seen an Biologics: Targets & Therapy 2007:1(1) 34
Geskey et al
increased prevalence of wheezing and asthma up to 20 years 
after RSV infection (Stein et al 1999; Korppi et al 2004).
RSV is an enveloped paramyxovirus with a single-stranded, 
negative sense RNA genome that encodes several proteins 
including the F (fusion) protein which promotes viral entry 
and syncytia formation, and the G (attachment) protein which 
promotes viral attachment to the cell. Two subgroups, A and 
B, either individually or together, are responsible for yearly 
outbreaks of RSV (Hall et al 1990). Disease severity is similar 
between subgroups (DeVincenzo 2004). Although various 
therapeutic modalities have been tried for RSV infection, 
treatment remains supportive with the aim of maintaining 
adequate oxygen saturation levels and hydration status (Sub-
committee on Diagnosis and Management of Bronchiolitis 
2006). The prevention of nosocomial infection by wearing 
gowns and gloves and establishing cohorts of patients and 
nursing staff remains an important cost-effective intervention 
in limiting the burden of RSV infection (Leclair et al 1987; 
Madge et al 1992; Macartney et al 2000). 
The development of a vaccine to prevent RSV infec-
tion remains a worldwide priority although previous 
attempts at vaccine development have been unsuccessful. 
In the 1960s, recipients of a formalin-inactivated vaccine 
suffered increased morbidity and mortality upon subse-
quent exposure to RSV (Chin et al 1969; Fulginiti et al 
1969). Since this time, subunit vaccines that target the F 
and G proteins of RSV, the delivery of vaccine antigens 
by live viral vectors, and live-attenuated vaccines have 
undergone testing in clinical trials and may hold promise 
as future vaccine candidates against RSV (Little-van den 
Hurk et al 2007). Passive immunization with RSV-IGIV, 
a purified immunoglobulin G pooled from human plasma 
selected for high titers of neutralizing antibody against 
RSV, and palivizumab, a humanized monoclonal antibody 
that binds RSV F protein, have been shown to reduce 
RSV-associated hospitalization (Groothuis et al 1993; The 
PREVENT Study Group 1997; The Impact-RSV Study 
Group 1998). Palivizumab has since become the preferred 
choice of RSV immunoprophylaxis because of its lack 
of concern with fluid overload, particularly in children 
with pre-existing cardiac or pulmonary disease (Simoes 
et al 1998). Ease of administration, lack of interference 
with immunization schedules, and decrease in parental 
work time loss and emotional costs are also reasons 
leading to the preference for palivizumab (Robbins et al 
2002). Parental partiality for palivizumab, particularly 
if administered in the home setting, has been shown to 
improve compliance and lead to a significant reduction 
in RSV-related hospitalization compared with treatment 
provided in a physician’s office (Golombek et al 2004).
Palivizumab safety, tolerance, 
pharmacokinetics, resistance
In preclinical trials, palivizumab was able to neutralize 
both subtype A and B strains of RSV and was 50- to 
100-fold more potent than RSV IVIG. Early animal trials 
demonstrated a >99% reduction of lung RSV titers in cot-
ton rats at mean serum concentrations of 25–30 μg/mL. All 
of the animals that achieved a serum concentration of at 
least 40 μg/mL had at least a 99% reduction in pulmonary 
RSV titer (Johnson et al 1997). In a phase I/II clinical 
trial of intravenously administered palivizumab, mean 
trough concentrations 30 days after infusion were 60.6 
μg/mL in patients who received 15 mg/kg palivizumab. 
These concentrations increased to 70.7 μg/mL 30 days 
after the second dose. Overall, 71% of patients had con-
centrations >40 μg/mL after the ﬁ  rst dose while 86% of 
patients achieved this concentration after the second dose 
(Subramanian 1998). In a phase I/II trial of intramuscular 
administration of 15 mg/kg palivizumab, the mean serum 
concentration of palivizumab at 30 days was 49 μg/mL and 
69.4 μg/mL 30 days after the second dose (Sáez-Llorens 
et al 1998). However, optimal dosing in premature infants 
may differ as trough levels 40 μg/mL in palivizumab 
recipients 30 weeks gestation with a mean weight of 1293 
± 236 g were achieved in only 23% of infants before the 
second dose, with mean trough levels of 32.2 ± 10.5 μg/mL 
in these subjects (Wu et al 2004).
RNA viruses, such as RSV, are susceptible to high rates 
of mutation which can occur during replication by virus-
encoded RNA-dependent RNA polymerase (Castro 
et al 2005). Incorporation of these mutations into the viral 
genome during replication could allow the emergence of 
viruses with a selective advantage. Although RSV escape 
mutants have been created in vitro by passing RSV in cell 
culture in the presence of palivizumab and tested in vivo in 
cotton rats leading to variable susceptibility of these escape 
mutants to palivizumab (Zhao et al 2004), surveillance 
of RSV isolates from hospitalized children demonstrated 
that none of the 371 RSV strains evaluated failed to bind 
palivizumab (DeVincenzo et al 2004). Palivizumab was 
safe and well-tolerated in phase I/II studies. There were 
no signiﬁ  cant changes in urinalysis, hematological values, 
blood urea nitrogen, creatinine, and transaminase levels 
(Sáez-Llorens et al 1998; Subramanian et al 1998). Addi-
tional safety data were collected in 565 patients in a phase Biologics: Targets & Therapy 2007:1(1) 35
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III and IV multicenter, single arm, open label study. Eleven 
patients (1.9%) discontinued the study because of an adverse 
event, 3 of which were deemed possibly or probably related 
to palivizumab (Groothuis 2001). Adverse events such as 
injection site reactions (2.3%), fever (1.5%), diarrhea (<1%), 
and nervousness/irritability (<1%) were comparable with 
the adverse events in the Impact-RSV trial, which did not 
demonstrate any signiﬁ  cant differences between children who 
received placebo and those who received palivizumab. 
In a review of adverse drug events in children younger 
than 2 years of age, Moore et al (2002) reported that palivi-
zumab accounted for 28% of reported serious or fatal adverse 
events to the US Food and Drug Administration’s (FDA) 
Adverse Events Reporting System. However, in a review 
of the 133 deaths reported to the FDA after palivizumab 
use, only 2% of children were full-term and born without 
congenital anomalies. This suggests that children who 
died after palivizumab treatment were at increased risk of 
death (Mohan 2004) and therefore no causal link has been 
established. Palivizumab has also been shown to be safe and 
well tolerated if used for a second season as no development 
of speciﬁ  c anti-palivizumab antibody response has been 
recorded (Lacaze-Masmonteil et al 2003; Null et al 2005).
Palivizumab efﬁ  cacy
IMpact-RSV was a multi-center, randomized, double-
blinded, placebo-controlled trial that enrolled 1502 children 
(500 placebo and 1002 palivizumab recipients). Eligible 
participants were 35 week’s gestational age and 6 months 
of age or 24 months old with a diagnosis of BPD requir-
ing ongoing medical treatment. Groups were well-matched 
demographically and for the presence of RSV risk factors, 
and more than 90% of both groups received all 5 monthly 
injections (The Impact-RSV study group 1998). Monthly 
prophylaxis resulted in a 55% relative reduction in RSV 
hospitalization (10.6% placebo, 4.8% palivizumab) with 
signiﬁ  cant relative reductions in children with BPD (39%) 
and premature children without BPD (78%). Signiﬁ  cant 
decreases in hospitalizations were seen in children greater 
than 5 kg (51%), less than or equal to 5 kg (57%), and in 
infants born before 32 weeks gestation (47%). Palivizumab 
recipients also had signiﬁ  cantly reduced hospital days, days 
with supplemental oxygen requirement, moderate/severe 
lower respiratory tract infections, and intensive care unit 
(ICU) admissions. There was no difference between the 
groups in incidence of mechanical ventilation and mortality 
rate. The number of adverse events between both groups 
was similar. The results of this study led to the licensure of 
palivizumab by the FDA for the prevention of RSV infection. 
Subsequently, guidelines from the American Academy of 
Pediatrics (AAP) and other professional organizations were 
developed (Table 1). Risk factors for RSV hospitalization 
in these countries can be found in Table 2.
Palivizumab has been shown to reduce the amount of 
RSV concentration in respiratory secretions obtained from 
mechanically ventilated children (Malley et al 1998) along 
with reducing nasal viral replication in premature hospital-
ized children who have received palivizumab prophylaxis, 
suggesting that the beneﬁ  ts of reduced hospitalization may 
come from a reduction in RSV load (DeVincenzo et al 
2003).
Palivizumab prophylaxis in BPD 
and prematurity
There are considerable disparities in reported RSV 
hospitalization rates for children born prematurely who 
have not received RSV immunoprophylaxis, ranging from 
3% (Joffe et al 1999) to 43.9% (Singleton et al 2003). 
Hospitalization rates vary by infant subgroups with rates of 
hospitalization increasing with decreasing gestational age 
and increasing in infants requiring oxygen therapy at 36 
weeks post-gestational age (PGA) compared with infants 
not requiring oxygen therapy (Boyce et al 2000; Stevens 
et al 2000). For example, Stevens et al (2000) estimated 
an RSV hospitalization rate of 13.9% for infants born at 
26 weeks gestation compared with 4.4% for those born 
Table 1 Comparison of recommendations for palivizumab prophylaxis by country
 CLD    28 weeks      29–32 weeks   33–35 weeks   Congenital heart disease
  2 years  12 mo  6 mo  6 months  + risk factors 
USA +  +    +  +  +
UK +         +
Canada +    +  +  +  +
Spain +    +  +  +  +
New Zealand  +  +    + if BW  1000 g
(Adapted from Vogel et al 2002)
Abbreviations: CLD, chronic lung disease; BW, birth weight.Biologics: Targets & Therapy 2007:1(1) 36
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at 30–32 weeks gestation and a 16.8% hospitalization rate 
for infants requiring oxygen therapy at 36 weeks. Boyce 
et al (2000) reported RSV hospitalization rates of 7.0% in 
infants 28 weeks gestation compared with 5.7% in infants 
33–36 weeks gestation and a 38.8% hospitalization rate in 
the ﬁ  rst year of life of infants with BPD. A comparison of 
RSV hospitalization rates in the US and other countries can 
be found in Table 3. International ﬁ  ndings were similar to 
those in the United States with the exception of Cilla et al 
(2005) who did not report an increasing hospitalization rate 
with decreasing gestational age. Although no explanation 
was offered for this ﬁ  nding, by combining gestational age 
with birth weight there was an increased hospitalization rate 
with decreasing gestational age. For example, the incidence 
of RSV hospitalization was 8.1% in infants 35 weeks gesta-
tion and weighing 2500 g compared with 4.9% in infants 
36–37 weeks gestation and weighing 2500 g.
Since the Impact-RSV trial, multiple studies have report-
ed on the hospitalization rates of children at high risk for RSV 
infection who have received palivizumab (Table 4). All of 
the studies reported hospitalization rates lower than Impact-
RSV’s 4.8% except Lacaze-Masmonteil et al (2002), whose 
7.6% rate may have reﬂ  ected the French Pediatric Society’s 
more stringent guidelines for palivizumab administration. 
The BPD rate was 81% in this study cohort compared with 
53% in the Impact-RSV trial. However, these studies did not 
have a control group to compare palivizumab prophylaxis 
versus no prophylaxis in the rates of RSV hospitalization, nor 
was the rate of RSV testing reported in most of the studies. 
Multiple studies since the IMpact-RSV trial have 
compared RSV-related hospitalizations between palivizumab 
and non-palivizumab recipients (Table 5). Six studies have 
demonstrated significant improvement in RSV-related 
hospitalization rates with palivizumab prophylaxis (Pedraz 
et al 2003; Singleton et al 2003; Grimaldi et al 2004, 2007; 
Kusuda et al 2006; Mitchell et al 2006) while 2 additional 
studies have demonstrated a trend toward significance 
(Shireman 2002; Resch 2006). Only three studies have not 
demonstrated an improvement in RSV-related hospitalization 
rates with palivizumab administration (Lacaze-Masmonteil 
et al 2004; Henckel et al 2004; Navér et al 2004). An 
explanation for these discordant results may be related to 
the variable timing and severity of RSV infection from 
year-to-year (Duppenthaler et al 2003; Terletskaia-Ladwig 
et al 2005), or differences related to the study populations 
with regard to known risk factors for RSV hospitalization. 
For example, if the rate of RSV infection peaks early in the 
season when infants have not reached a therapeutic trough 
level of palivizumab the rate of RSV-related hospitalizations 
may be increased compared with a season characterized by 
a later peak in RSV activity. Also, if the RSV season was 
mild when palivizumab was administered compared with a 
previous year when the RSV season was more severe, the 
rates of RSV hospitalization in the palivizumab group may 
demonstrate a more signiﬁ  cant improvement in the rates of 
hospitalization. 
Consistent with the Impact-RSV trial, none of these 
studies reported a signiﬁ  cant difference between groups in the 
rate of mechanical ventilation and mortality. In a study that 
speciﬁ  cally looked at the ICU admission rate before and after 
palivizumab availability there was no signiﬁ  cant difference 
Table 2 Risk factors for hospitalization for RSV by different 
countriesa
Author Year (Country)  Risk factors for hospitalization
Carbonell-Estrany 2000 (Spain)  Chronic lung disease
  Living with school age siblings
Cilla 2005 (Spain)  Birth weight 2500 g
  Maternal age at delivery 25 years
  Birth in the second half of the year
 Prematurity
 Suburban  residence
   Congenital heart disease
Vogel 2002 (New Zealand)  Home oxygen 
  28 weeks gestation
Joffe 1999 (USA)  32 weeks gestation
  28 days of oxygen usage
  NICU discharge between Septem-
 ber/November
Boyce 2000 (USA)  Congenital heart disease
  1 sibling
 White  race
 Maternal  smoking
 Maternal  education  12 years
 Rural  residence
Iwane 2004 (USA)  12 months age
 African-American/Hispanic 
 Male  gender
  Underlying chronic illness
Deshpande 2004 (UK)  Need for assisted ventilation 
  during neonatal period
  Discharge home on oxygen 
 therapy
Broughton 2005 (UK)  Number of siblings
  Maternal smoking in pregnancy
Wang 1995 (Canada)  Aboriginal race
 Age  6 weeks
  Underlying pulmonary disease
 Prematurity
  Congenital heart disease
 Immunosuppression 
aRisk factors for hospitalization are reported only once per country.
Abbreviations: RSV, respiratory syncytial virus; NICU, neonatal intensive care unit.Biologics: Targets & Therapy 2007:1(1) 37
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in the rate of mechanical ventilation or mortality (Prais et al 
2005). One of the reasons that palivizumab may not have an 
effect on these outcomes is that most ICU admissions did 
not meet AAP guidelines for the use of palivizumab (Numa 
2000; Cilla et al 2006; Prais et al 2005). 
Palivizumab prophylaxis in 33–35 
weeks gestation age
Despite most developed countries utilizing palivizumab in 
infants born less than 33 weeks gestational age (Table 1), 
controversy exists on administering palivizumab to infants 
born between 33 and 35 weeks gestation. During the ﬁ  rst 
year of life, the RSV hospitalization rate for children born 
at 33–35 weeks gestation in the United States is comparable 
to those born between 29–32 weeks gestation (Boyce et al 
2000). In 2001, 5.5% of live births in the US were born at 
32–35 weeks gestation (National Center for Health Statistics 
2001), and although the Impact-RSV trial (The Impact-RSV 
Study Group 1998) demonstrated an 80% reduction in RSV 
hospitalization in palivizumab recipients compared with 
placebo for this gestational age group (9.8% vs 2.0%), the 
potential cost of administering palivizumab to such a large 
group of infants was recognized by the AAP and factored into 
their recommendations (Committee on Infectious Diseases 
and Committee on Fetus and Newborn 2003). They suggested 
that practitioners consider palivizumab prophylaxis if two or 
more of the following risk factors were present: child care 
attendance, school-aged siblings, exposure to environmen-
tal air pollutants, congenital airway anomalies, or severe 
neuromuscular disease. Risk factors for RSV hospitaliza-
tion in this age group were studied prospectively in Spain 
(Figueras-Aloy et al 2004) and Canada (Law et al 2004). In 
Spain, age 10 weeks at start of RSV season, breast-feeding 
2 months, at least 1 school age sibling, at least 4 people 
living in the household (excluding the infant and school-age 
siblings), and a family history of wheezing were signiﬁ  cantly 
associated with an increased risk of RSV hospitalization 
(Figueras-Aloy et al 2004). In Canada, signiﬁ  cant risk factors 
for RSV hospitalization in this age group included day-care 
attendance, November through January birth, preschool sib-
lings, birth weight less than the 10th percentile, male gender, 
at least 2 smokers in the home and more than 5 people in the 
home, including the infant (Law et al 2004). Further study is 
necessary in this age group before deﬁ  nitive, evidence-based 
recommendations can be made.
Palivizumab prophylaxis 
in congenital heart disease
A total of 1287 children less than or equal to 2 years of age 
with hemodynamically signiﬁ  cant CHD that was uncorrected 
or palliated were randomized in a double-blind, placebo-
controlled trial conducted in Canada, France, Germany, 
Sweden, United Kingdom, and the United States. Recipi-
ents were given either 15 mg/kg of palivizumab or placebo 
Table 3 RSV hospitalization rates in premature infants without palivizumab immunoprophylaxis since 2000
Author Year (Country)   RSV hospitalization rate (gestational age)  RSV hospitalization rate (BPD)
Boyce 2000 (USA)   7.0% (28 wks); 6.6% (29–33 wks);   38.8%
 5.7%  (33–36 wks)
Stevens 2000 (USA)   11.2% (32 wks)   16.8%a
Weigl 2001(Germany)   2.0% (32 wks);1.2% (32–37 wks) 
Liese 2003 (Germany)   5.2% (35 wks)   15%
Carbonell-Estrany 2000 (Spain)   13.4% (32 wks)
Carbonell-Estrany 2001 (Spain)   13.1% (32 wks)
Greenough 2001 (UK)     19%
McCormick 2002 (UK)   7.3% (32 wks), 6.4% (35 wks)
Cilla 2006 (Spain)   4.4% (33 wks), 7.8% (33–35 wks)
aResult reported as respiratory support beyond 36 weeks post-conceptual age.
Abbreviations: RSV, respiratory syncytial virus; BPD, bronchopulmonary dysplasia.
Table 4 RSV-related hospitalization rate after introduction of 
palivizumab
Author Year (Country)   RSV hospitalization rate
Sorrentino 2000 (US)   2.3%
Cohen 2000 (US)   2.4% (3.9% CLD)
Winchester 2002 (Puerto Rico)   3.0% 
Oh 2002 (Canada)   2.4% (6.0% BPD, 1.6% prematurity)
Lacaze-Masmonteil 2002 (France)   7.6% (9.0% BPD)
Palivizumab Outcomes   2.9% (5.8% CLD, 2.1% prematurity)
Registry 2003 (US) 
Romero 2003 (US)   1.5%
Abbreviations: RSV, respiratory syncytial virus; CLD, chronic lung disease; BPD, 
bronchopulmonary dysplasia.Biologics: Targets & Therapy 2007:1(1) 38
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via i.m. injection every 30 days for a total of 5 doses. There 
were no signiﬁ  cant differences between the groups in demo-
graphic characteristics, RSV risk factors, and characteristics 
of CHD at study entry. Palivizumab prophylaxis was 
signiﬁ  cantly associated with a 45% relative reduction in 
hospitalization rates. RSV hospitalization rates were 9.7% 
in the placebo group and 5.3% in the palivizumab group. 
Although the study was not powered for subgroup analysis, 
reductions in RSV hospitalization were signiﬁ  cantly greater 
in the non-cyanotic group (29% relative reduction in the 
cyanotic group, 58% relative reduction in the non-cyanotic 
group). Length of hospitalization stay and hospital days with 
increased oxygen requirement were also signiﬁ  cantly reduced 
in the palivizumab recipients. An expected, but extremely 
important finding was that mean serum palivizumab 
concentrations were reduced by 58% after cardiopulmonary 
bypass leading to a recommendation from the AAP that 
palivizumab be administered postoperatively once medically 
stable (American Academy of Pediatrics 2003). 
The low mortality rate in the study cohort resulted in 
an inability to determine the impact of palivizumab on 
death reduction from RSV among palivizumab recipients 
(2 palivizumab recipients died from RSV infection compared 
with 4 placebo recipients). Adverse events were similar in 
both groups (Feltes et al 2003). A similar rate of hospi-
talization (4.6%) was found in 108 Japanese infants with 
CHD who received palivizumab with no children requiring 
mechanical ventilation and no mortality (Saji et al 2005). 
Other investigators have found similar or lower incidences 
of RSV hospitalizations in patients with hemodynamically 
signiﬁ  cant CHD than the 9.7% rate reported in the placebo 
arm of Feltes et al (2003) who were not given palivizumab 
prophylaxis (Duppenthaler et al 2004; Meberg and Bruu 
2006). RSV hospitalization rates in patients with severe CHD 
Table 5 RSV hospitalization rates in premature infants with and without palivizumab prophylaxis
Author  Location  Design  Enrolled  RSV hospitalization rate 
           No Prophylaxis  Prophylaxis
Shireman 2002  US    Retrospective Medicaid  11.7%    5.8% 
      cohort   administration claims
Singleton 2003   US     Retrospective   AAP recommendations   43.9%   15.0%a
     cohort   +  32 wks instead of 32 wks
        and 36 wks with signiﬁ  cant
        respiratory distress during 
       newborn  hospitalization
Lacaze-   France    Multicenter  <33 wks   7.2%   6.1% 
Masmonteil 2004      prospective
     longitudinal  cohort
Resch 2006   Austria   Observational   29–32 wks   8.1%   3.3%b 
Henckel 2004   Sweden  Retrospective   32 wks   3.9%   2.7%c
      cohort  CLD with therapy   6.8%   7.3%d
Kusuda 2006   Japan    Non-randomized   29–35 wks   5.7%   4.0%a 
     questionnaire  CLD  8.0%    10.3% 
       28 wks   4.6%   5.2% 
Grimaldi 2004   France    Prospective   32 wks + BPD   46.2%   11.8%, 3.8%a,e
     observational  cohort 
Pedraz 2003   Spain     Prospective cohort  32 weeks +   13.25%   3.95%a
       6 mo 
Navér 2004   Sweden   Prospective cohort   36 wks   3.8%   4.1%f 
Mitchell 2006   Canada   Population-based   BPD + oxygen   7.3%   3.0%a
     observational    32 wks + 6 mo 
Grimaldi 2007   France    Prospective   30 wks – BPD   13.5%   1.1%a 
     observational   
adenotes statistical signiﬁ  cance (p < 0.05).
bStudied adequate prophylaxis versus inadequate prophylaxis.
cSeven ICU admissions not included in hospitalization rate for the no prophylaxis group = 5.1% (29/567)
dTwo ICU admissions not included in hospitalization rate for CLD with therapy in prophylaxis group = 8.6% (13/151) and 1 ICU admission not included in hospitalization 
rate for CLD with therapy in no prophylaxis group = 9.1% (4/44).
eNo prophylaxis group encompassed 1999–2000 while 11.8% and 3.8% refer to 2000–01 and 2001–02, respectively.
fHospitalization rate calculated at <36 weeks, however, palivizumab administered 76% of time according to Swedish recommendations (children < 2years with CLD requir-
ing continuous therapy during last 6 months and children < 26 weeks and <6 months age at start of RSV season).
Abbreviations: RSV, respiratory syncytial virus; AAP, American Academy of Pediatrics; CLD, chronic lung disease; BPD, bronchopulmonary dysplasia; ICU, intensive care unit.Biologics: Targets & Therapy 2007:1(1) 39
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in Norway were 9.2% (Meberg and Bruu 2006) and only 
2.4% in Switzerland (Duppenthaler et al 2004).
Palivizumab in bone marrow 
transplant recipients
Palivizumab has been shown to reduce pulmonary RSV titers 
in immunosuppressed cotton rats. However, multiple doses of 
palivizumab at 4-day intervals were needed to reduce rebound 
viral replication (Ottolini et al 2002). Hematopoietic stem cell 
transplant (HSCT) recipients were administered 15 mg/kg of 
palivizumab intravenously in two phase 1 studies. The ﬁ  rst 
study enrolled 6 HSCT patients who didn’t have active RSV 
infection whereas the second study enrolled 15 patients who 
had active RSV infection (12 lower respiratory tract, 3 upper 
respiratory tract). Aerosolized ribavarin was administered 
in all of study two’s 15 patients. The mean serum half-life 
of palivizumab was 22.4 days in study one and 10.7 days 
in study two, while serum concentrations >40 μg/mL were 
maintained for 21 days in 83% of study one patients and 
73% of study two patients. RSV was detected by culture 
on day 21 in 16.7% of patients. Palivizumab appeared to be 
safe and well tolerated in HSCT recipients with 10 (83%) of 
12 patients who had lower respiratory tract RSV infection 
surviving (Boeckh et al 2001). A decision analysis model 
recently concluded that there would be a 10% absolute in-
crease in survival from RSV-related lung disease in pediatric 
bone marrow transplant (BMT) patients if they received 
palivizumab prophylaxis with the number needed to treat of 
12 to prevent 1 death (Thomas et al 2007). Clinical guidelines 
from the American Society of Transplantation recommend 
using either palivizumab or RSV immune globulin intrave-
nous in combination with ribavarin if patients have RSV 
lower respiratory tract disease. The use of palivizumab in 
children less than 1 year of age who receive their transplant 
during RSV season can be considered (Community-acquired 
respiratory viruses 2004). 
Palivizumab in cystic ﬁ  brosis
In a study of 22 infants with cystic ﬁ  brosis (CF) less than 
2 years of age compared with 27 age-matched controls, 
CF children infected with RSV were 4 times more likely 
to develop lower respiratory tract infection, had a greater 
risk of hospitalization, and developed a decrease in lung 
function that lasted for several months (Hiatt 1999). A 
national questionnaire survey of CF centers in the UK found 
that 16/143 (11.2%) of CF infants were hospitalized with 
RSV without ICU admissions or deaths. Palivizumab was 
administered to 14/143 infants (9.8%) with 1 infant (7.1%) 
requiring hospitalization after receiving prophylaxis. Two 
of the three centers that used palivizumab had a negotiated 
funding agreement and offered RSV prophylaxis to children 
less than 1 year of age. Survey respondents were more 
likely to prescribe palivizumab if funding were not an 
issue (McCormick and Southern 2007). In a phase IV study 
examining the safety of palivizumab in 186 children with 
CF, 92 children were randomized to palivizumab and 94 
children were randomized to placebo. The overall adverse 
events were similar in both groups and no serious adverse 
events were related to palivizumab. The hospitalization rate 
was 1.1% in both groups (Cohen et al 2005).
Palivizumab usage in hospitalized 
infants and children
Fifty-nine previously healthy children less than or equal 
to 2 years of age hospitalized with acute RSV infec-
tion were given IV palivizumab or placebo in a phase 
I/II, multicenter, randomized, double-blind, placebo-
controlled, escalating-dose clinical trial (Sáez-Llorens 
et al 2004). After at least 12 children received 5 mg/kg 
dose of palivizumab and were followed for at least 5 days 
without experiencing dose-limiting toxicity or a serious 
adverse event, dose-escalation to 15 mg/kg palivizumab 
occurred. There were no significant differences in adverse 
events between the groups. Mean serum concentrations 
of palivizumab 60 minutes after administration was 
61.2 and 303.4 μg/mL in the 5- and 15-mg/kg groups, 
respectively. At 30 days mean serum concentrations of 
palivizumab were 11.2 and 38.4 μg/mL in the 5- and 
15-mg/kg groups, respectively. The small number of 
patients randomized in this study was not sufficiently 
powered to show efficacy of adopting this strategy in 
the management of children hospitalized with acute RSV 
infection; however, there were no significant differences 
in clinical outcomes between groups. Additionally, a 
randomized, double-blind, placebo-controlled trial of 
35 mechanically ventilated children <2 years of age with 
RSV infection demonstrated no differences in measures 
of disease severity between groups (Malley et al 1998), 
suggesting the lack of therapeutic benefit to palivizumab 
administration during active RSV infection.
Palivizumab has been used to control outbreaks of 
nosocomial RSV infection in premature infants (Cox et al 
2001; Abadesso et al 2004). The implementation of standard 
infection control measures that were adopted in addition 
to the administration of palivizumab makes it difﬁ  cult to 
assess whether palivizumab was solely, or even partially, Biologics: Targets & Therapy 2007:1(1) 40
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responsible for halting further outbreak of RSV infections 
(Cox et al 2001). However, the use of palivizumab may be 
effective in halting further cases of RSV if infection control 
measures fail (Abadesso et al 2004).
Pharmacoeconomic considerations 
of palivizumab usage
One of the most contentious issues surrounding palivizumab 
use is its cost-beneﬁ  t ratio, which was noted by the American 
Academy of Pediatrics in their revised recommendations 
for RSV immunoprophylaxis (Meissner and Long 2003). 
It is difﬁ  cult to evaluate and interpret pharmacoeconomic 
analyses. For example, 67% of submissions by pharma-
ceutical companies to the Department of Health and Aged 
Care in Australia for the purpose of getting the cost of drugs 
reimbursed had signiﬁ  cant problems. Uncertainty in the 
estimates of comparative clinical efﬁ  cacy, modeling issues 
such as clinical assumptions and cost estimates, calculation 
errors, and disagreement in choice of comparator were all 
noted (Hill et al 2000). 
A systematic review of 12 studies that performed 
a pharmacoeconomic analysis of immunoprophylaxis 
agents against RSV found conﬂ  icting results as to whether 
palivizumab or RSV-IGIV was cost-effective in different 
infant subgroups. The authors suggested that neither agent 
was considered cost-effective if administered according 
to AAP guidelines (Kamal-Bahl et al 2002). Differences 
in study methods and assumptions regarding the cost of 
RSV-related hospitalization, number of doses administered, 
weight of infants receiving immunoprophylaxis, and whether 
the study had ﬁ  nancial support from the manufacturer of 
the two agents contributed to the disparate ﬁ  ndings. A 
recent cost-effectiveness analysis was conducted from a 
societal perspective in a hypothetical cohort of infants born 
between 26 and 32 weeks gestation without chronic lung 
disease. Factors measured included parental lost wages for 
an infant RSV-related emergency department (ED) visit and 
hospitalization, costs for asthma-related care, palivizumab 
acquisition, injection administration, ED services, and RSV 
hospitalization. Palivizumab was not found to be cost-
effective, irrespective of gestational age, if there was no 
causal relationship between RSV and asthma. Palivizumab 
was considered cost-effective in infants born at 26 and 29 
weeks gestation who had a reduced quality of life due to 
asthma and if palivizumab costs were reduced to 25% of their 
current value for these infants (Elhassan et al 2006). A more 
restrictive guideline that offered palivizumab to infants born 
at 26 or 27 weeks gestation was suggested, which is similar 
to Swedish guidelines recommending the use of palivizumab 
in infants less than 6 months of age who were born before 
26 weeks gestation (Swedish Consensus Group 2001) and 
guidelines in New Zealand which recommend palivizumab 
be offered to infants born at less than or equal to 28 weeks 
gestation, although best estimates did not ﬁ  nd a positive 
cost beneﬁ  t in any group (Vogel et al 2002). A systematic 
review in the United Kingdom suggested that palivizumab 
is cost-effective if the probability of RSV hospitalization is 
at least 31% (Simpson and Burls 2001), leading to a recom-
mendation from Embleton et al (2005) that pre-term infants 
without other risk factors such as chronic lung disease or 
hemodynamically signiﬁ  cant cardiac disease should not be 
offered palivizumab.
Similar concerns of cost-effectiveness of palivizumab 
administration in CHD have also been raised. A decision 
analysis model by Yount and Mahle (2004) found the cost 
of providing palivizumab was 3 times more expensive than 
1 day in the hospital and was cost-effective only if one 
assumed that palivizumab reduced in-hospital mortality 
from RSV infection in children with CHD. Another review 
found no evidence that palivizumab administration given 
prior to hospital discharge leads to reduced hospitalization 
in premature infants compared with administration after 
hospital discharge. The practice of requiring palivizumab 
after discharge represents signiﬁ  cant potential cost avoidance 
to hospitals since many third-party payers do not separately 
reimburse hospitals for in-hospital immunizations (Geskey 
et al 2004) and less than 1% of infants who received palivi-
zumab in the home setting were subsequently hospitalized 
with RSV infection (Golombek et al 2004).
Future directions
Future studies are required to determine whether prophylaxis 
with palivizumab decreases the prevalence of asthma in chil-
dren with known risk factors. This area of research is crucial 
as palivizumab has been shown in vitro to block airway per-
meability in human bronchial epithelial cell cultures (Kilani 
et al 2004) and also lung inﬂ  ammation, airway obstruction, 
and airway hyper-responsiveness in mice (Mejías et al 2004). 
The recent development and study of MEDI-524, which has 
more potent anti-RSV neutralizing activity than palivizumab, 
demonstrated reduced lung RSV loads and signiﬁ  cantly less 
inﬂ  ammation than palivizumab when given 24 hours prior to 
inoculation with RSV in a mouse model. However, when given 
after infection, neither monoclonal antibody was able to reverse 
the lung injury that had already occurred after RSV infection 
(Mejías et al 2005). This demonstrates the continued need for a Biologics: Targets & Therapy 2007:1(1) 41
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vaccine to reduce the substantial morbidity that occurs with RSV 
infection and highlights that the engineering of even more potent 
monoclonal antibodies that have the potential to reduce not only 
the RSV hospitalization rate but also the long-term pulmonary 
abnormalities that may occur from RSV infection.
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